4th May 2016

Luxury & Consumer Goods

Hugo Boss

Price EUR57.65

Bloomberg Reuters 12-month High Market Cap (EU Ev (BG Estimate Avg. 6m daily vo 3y EPS CAGR	BOSS GR BOSG_p.DE 113.8 / 51.3 4,059 4,141 418.7 -5.0%			
	1 M	3 M	6 M 3	1/12/15
Absolute perf.	2.9%	-18.2%	-38.4%	-24.7%
Pers & H/H Gds	-0.1%	-0.3%	-6.6%	-2.2%
DJ Stoxx 600	0.7%	1.9%	-11.3%	-8.3%
YEnd Dec. (EURm)	2014	2015	2016e	2017e
Sales	2,572	2,809	2,803	2,956
% change		9.2%	-0.2%	5.5%
Reported EBITDA	571	590	495	544
Reported EBIT	448.7	447.7	349.8	393.3
% change		-0.2%	-21.9%	12.5%
Net income	333.3	319.3	257.5	295.4
% change		-4.2%	-19.4%	14.7%
	2014	2015	2016e	2017e
Operating margin	17.4	15.9	12.5	13.3
Net margin	13.0	11.4	9.2	10.0
ROE	39.5	34.0	25.4	25.4
ROCE	33.2	29.1	22.3	23.9
Gearing	5.1	8.8	4.2	-4.2
(EUR)	2014	2015	2016e	2017e
EPS	5.04	4.67	3.82	4.32
% change	-	-7.3%	-18.3%	13.2%
P/E	11.4x	12.3x	15.1x	13.3x
FCF yield (%)	7.0%	7.2%	7.6%	8.2%
Dividends (EUR)	3.62	3.62	3.20	3.65
Div yield (%)	6.3%	6.3%	5.6%	6.3%
EV/Sales	1.6x	1.5x	1.5x	1.4x
EV/EBITDA	7.2x	7.0x	8.3x	7.4x
LV/LDIIDA	7.20	7.07	0.57	7.48



FY16 outlook requires a clear improvement in persistently challenging market conditions

Fair Value EUR77 vs. EUR80 (+34%)

NEUTRAL

During the conference call yesterday, CFO Mark Langer updated us on the two main initiatives that are underway (i.e. category migration in the US and price adjustments in China) and which should pay off mainly in H2. This is why the groups expects more beneficial sales and earnings momentum over the second half of the year, especially since the group has identified additional cost savings of EUR50m. We remain a bit more cautious than the group's targets after some minor adjustments (mostly FX). Neutral recommendation and FV nudged down to EUR77 vs. EUR80.

ANALYSIS

- US: negative underlying trends are not helping. The sales decline in the US (-16% FX-n) was broadly similar between Retail and Wholesale (59%-41% of 2015 US sales respectively), confirming that the US premium apparel market is clearly affected by a number of headwinds (deflationary trends, declines in footfall, lack of tourists). In the meantime the group continues to upgrade its distribution in both channels: improving execution and focusing on achieving healthy inventory levels (almost completed) in its own stores and continuing the category migration and some takeovers to better control distribution. However the positive results from these initiatives are slower to appear given the sluggish market conditions.
- Mainland China: price adjustments were welcomed by consumers. Indeed the 10% rebound in volumes in Q1 encompassed the 2015 F/W collection and the 2016 S/S collection on which prices were adjusted by 20%. Consequently, the increase in volumes for this Spring collection was even higher, revealing a relatively high price elasticity as well as Chinese consumers' prompt reactivity, also backed by a successful digital marketing campaign. Management is confident in a gradual recovery over the rest of the year, but the negative trends in HK-Macau (double-digit decline) have not stabilised yet.
- Hugo Boss is aggressive on cost savings... The group has identified additional cost savings of around EUR50m over 2016 thanks to: (i) the first renegotiations of rental contracts, mostly in China, while the group is currently reviewing its rents with landlords concerning larger stores, (ii) more selective and targeted marketing expenses (=> difference between the initial marketing spend budget and the current budget = cost savings) and (iii) fewer store openings (~15 DOS) than the initial MT target of 20-25 openings. Last but not least, Mark Langer also declared that he was analysing the 15-20 least profitable stores, which could lead to some store closures.
- ... and is comfortable with FY16 guidance. In light of this difficult start to the year, FY16 targets are becoming more challenging but management remains confident in achieving them: (i) GM should remain stable (Q1: -140bp) as the headwinds (inventory write-downs, price adjustments, discounts) should gradually diminish and the channel-mix will remain favourable, (ii) adj. EBITDA is expected to decrease in low double-digits (Q1: -29%) thanks to a less harmful operating deleverage (company guides on a flat SSSG over 2016 vs. -6% in Q1) combined with tight opex control (o/w cost-savings).
- We have nudged down our FY16 estimates by 3%. These adjustments are a consequence of the Q1 publication (below our expectations) and reflect a more negative FX impact at the top line level. Like the consensus estimates, we remain more cautious than the group's targets: we expect 1% FX-n growth (vs. +2% previously) and a 15% decline in adj. EBITDA, close to the CS expectations prior to yesterday's publication.

VALUATION

 The group has clearly implemented a proactive and ambitious reset plan but the FY outlook requires a significant improvement over H2 and the group noticed no signs of a recovery in April. Since visibility remains low, we maintain our Neutral recommendation pending the first positive impact of these initiatives on the group's operating performance. Our FV is slightly reduced to EUR77 vs. EUR80 following our estimates adjustments.

NEXT CATALYSTS

AGM on 19th May // H1 results on 5th August. <u>Click here to download</u>



Analyst: Cédric Rossi 33(0) 1 70 36 57 25 crossi@bryangarnier.com **Consumer Analyst Team:** Nikolaas Faes Loïc Morvan Antoine Parison Virginie Roumage

BRYAN, GARNIER & CO

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a			
DUI	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of			
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock			
	will feature an introduction outlining the key reasons behind the opinion.			

- NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
- SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 57,9%

NEUTRAL ratings 33,6%

SELL ratings 8,6%

Research Disclosure Legend

1	Bryan Garnier shareholding n IssuerBryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").		No	
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more member of the Bryan Garnier Group.		
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report		
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer of in any related derivatives.		
5	Lead/co-lead manager	d manager In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.		
6	Investment banking agreement A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.		No	
7	Research agreement A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.		No	
8	Analyst receipt or purchase of shares in Issuer			
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.		
10	Corporate finance client	borate finance client In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.		
11	Analyst has short position The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.		No	
12	Analyst has long position The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.		No	
13	Bryan Garnier executive is an officer A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.		No	
14	Analyst disclosure The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.		Yes	
15	15 Other disclosures Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).		No	

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

BRYAN, GARNIER & CO

London	Paris	New York	Munich	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001 Tel +91 11 4132 6062
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	+91 98 1111 5119
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	Fax +91 11 2621 9062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Geneva
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			rue de Grenus 7 CP 2113
Financial Conduct Authority (FCA)	Autorité de Contrôle prudential et de			Genève 1, CH 1211
	resolution (ACPR)			Tel +4122 731 3263

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Fax+4122731 3243 Regulated by the FINMA

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited and should not rely on it for any purposes whatsoever.

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not

aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..

BRYAN, GARNIER & CO